Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

By Nikita Chaurasia  | Date: 2020-05-18

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial for assessing a possible coronavirus vaccine.

The Prime Minister of Canada, Justin Trudeau made this announcement on Saturday during his daily address to the nation.

Trudeau stated that research and development require time, and should be done right. However, despite the fact, this is a good news. The National Research Council would be working closely alongside the manufacturers, so in case the clinical trials are a success, the coronavirus vaccine can be manufactured and distributed at scale.

The clinical trials have been authorized by Health Canada and would be carried out at the CCfV (Canadian Centre for Vaccinology) at the Dalhousie University, Halifax. The CCfV team comprises 45 people working together on a potential vaccine candidate from CanSino Biologics.

Health Canada, while speaking about the trial, stated that the approval for going ahead with the trial was done after a careful review of the submitted trial application, which fulfilled the necessary quality and safety requirements.

Researchers stated that approximately 600 participants would be required to commence the clinical study.

Scott Halperin, CCfV Director and professor of immunology, pediatrics, and microbiology at Dalhousie University, stated that they would be further building upon the trials that have already started in China.   

Halperin further added that a vaccine strain known as Ad5-nCoV utilizes another virus which is modified to not cause infection within humans. It expresses a COVID-19 antigen called spike protein on its surface. If the trial participants create antibodies to tackle this antigen, then the formulation might prove helpful against the coronavirus.

Halperin hopes that the clinical trials would start in the coming two weeks once the team receives its approval from the ethics board.

Less than 100 participants of different ages would be tested in Phase 1. Phase 2 is expected to have more than 500 participants ranging between 18 to 85 years of age.

 

Source credit: https://www.cbc.ca/news/canada/nova-scotia/first-canadian-vaccine-trials-covid-19-halifax-1.5573283

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

Swiftly achieves Unicorn status with $100M Series C led by BRV Capital

By Nikita Chaurasia

Swiftly Systems has reportedly achieved unicorn status, securing in funding through a Series C round. The prominent BRV Capital Management led this funding initiative. According to the earlier reports, Swiftly was adopted by hundreds of consumer b...

Rainforest nations unify to demand cash for climate & biodiversity preservation

Rainforest nations unify to demand cash for climate & biodiversity preservation

By Nikita Chaurasia

As per the reports, twelve nations with rainforests united to establish a collective initiative aiming to address climate change and safeguard biodiversity at summit held in Brazil. The declaration, titled "United for Our Forests," emerged ...

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

AI Chatbot, Llama 2, unveiled by Meta for commercial use via Microsoft

By Nikita Chaurasia

Meta Platforms has recently introduced Llama 2, an artificial intelligence large language model, for commercial use in collaboration with major cloud providers like Microsoft. Instead of charging for access or usage, Meta aims to share the model with...

Moderna signs agreement to explore mRNA medicines in China

Moderna signs agreement to explore mRNA medicines in China

By Nikita Chaurasia

Moderna Inc, a leading vaccine manufacturer, reportedly announced on Wednesday that it has entered into a memorandum of understanding (MoU) and a land collaboration agreement aimed at exploring opportunities for researching, developing, and producing...

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

Nike and Epic Games collaborate to launch Airphoria NFT in Fortnite

By Nikita Chaurasia

The American footwear design & manufacturing company, Nike and Epic Games, the creators of the popular online game Fortnite, have joined forces in an exciting new collaboration. The partnership aims to bring about a groundbreaking change in the d...